Loading…
Loading…
XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global Healthcare Conference. Management is scheduled to present on Tuesday, September 15, 2026, at 11:25 a.m. ET.
"I'll give you 950 billion reasons to buy bonds right now," says Thomas Hayes, who gives a contrarian take on why investors should bolster their portfolios in fixed income. He discusses the "seasonality effect," a crowded AI trade, a complicated geopolitical picture, and a steady rise in crude oil as components he sees leading a lasting bond rally.
New system completes the Surity™ portfolio of external catheters for both men and women Integrates into daily routines to help support management of urinary incontinence at home Designed to operate quietly overnight, new Surity™ System helps minimize nighttime interruptions to support comfort and rest MÖLNDAL, Sweden, Aug. 19, 2026 /PRNewswire/ -- Wellspect HealthCare today announced the U.S. launch of the Surity™ Urinary Management System, a discreet at-home urine collection device designed to support people living with urinary incontinence and those who help care for them. This completes the full Surity™ portfolio in the U.S., following the introduction of the Surity™ Female and Male External Catheters earlier this year.
Empowered Funds LLC increased its holdings in DENTSPLY SIRONA Inc. (NASDAQ: XRAY) by 515.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 126,601 shares of the medical instruments supplier's stock after acquiring an additional 106,024 shares during the
DENTSPLY SIRONA NASDAQ: XRAY reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europe.
DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.